Wolters, Frank J; Hilal, Saima; Leening, Maarten J G; Kavousi, Maryam; Ghanbari, Mohsen; Franco, Oscar H; Hofman, Albert; Koudstaal, Peter J; Vernooij, Meike W; Ikram, M Kamran; Bos, Daniel; Ikram, M Arfan (2022). Plasma amyloid-β40 in relation to subclinical atherosclerosis and cardiovascular disease: A population-based study. Atherosclerosis, 348, pp. 44-50. Elsevier 10.1016/j.atherosclerosis.2022.03.025
|
Text
Wolters_Atherosclerosis_2022.pdf - Published Version Available under License Creative Commons: Attribution (CC-BY). Download (1MB) | Preview |
BACKGROUND AND AIMS
We aimed to determine associations of plasma amyloid-β40 (Aβ40) with subclinical atherosclerosis and risk of atherosclerotic cardiovascular disease (ASCVD) in the general population.
METHODS
Between 2002 and 2005, plasma Aβ40 was measured by single molecule array (SiMoA®) in 3879 participants of the population-based Rotterdam Study (mean age: 71 years, 61% female). Subclinical atherosclerosis was quantified as computed tomography-assessed calcification volumes. We determined the association of Aβ40 with calcification volumes and clinical ASCVD event risk, and repeated the analyses for ASCVD in a replication cohort of 1467 individuals.
RESULTS
Higher levels of Aβ40 were associated with increased volumes of calcification in the coronary arteries and to a lesser extent extracranial carotid arteries, independent of traditional cardiovascular risk factors. Of all 3879 participants, 748 developed ASCVD during a median 9.7 years of follow-up. In age- and sex-adjusted models, higher Aβ40 predisposed to a minor increase in ASCVD risk (HR [95%CI]: 1.11[1.02-1.21] per 1-SD increase in Aβ40), driven by coronary heart disease (HR: 1.17[1.05-1.29]) rather than stroke (HR: 1.04[0.93-1.16]). However, excess risk of clinical outcomes was largely explained by baseline differences in cardiovascular risk factors and attenuated after further adjustment (for ASCVD- HR: 1.05[0.96-1.15] and for CHD- HR: 1.08[0.96-1.20]). Results were similar in the replication cohort, with highest risk estimates for CHD (HR: 1.24[1.04-1.48]) in age- and sex-adjusted models, attenuated after adjustment for cardiovascular risk factors (HR: 1.15[0.96-1.39]).
CONCLUSIONS
In this population-based study, higher plasma amyloid-β40 is associated with subclinical atherosclerosis, but not risk of first-ever ASCVD after accounting for traditional cardiovascular risk factors.
Item Type: |
Journal Article (Original Article) |
|---|---|
Division/Institute: |
04 Faculty of Medicine > Pre-clinic Human Medicine > Institute of Social and Preventive Medicine (ISPM) |
UniBE Contributor: |
Franco Duran, Oscar Horacio |
Subjects: |
600 Technology > 610 Medicine & health 300 Social sciences, sociology & anthropology > 360 Social problems & social services |
ISSN: |
0021-9150 |
Publisher: |
Elsevier |
Language: |
English |
Submitter: |
Doris Kopp Heim |
Date Deposited: |
28 Apr 2022 10:43 |
Last Modified: |
05 Dec 2022 16:19 |
Publisher DOI: |
10.1016/j.atherosclerosis.2022.03.025 |
PubMed ID: |
35452865 |
Uncontrolled Keywords: |
Amyloid Atherosclerosis Cardiovascular disease Coronary heart disease Stroke |
BORIS DOI: |
10.48350/169590 |
URI: |
https://boris.unibe.ch/id/eprint/169590 |
Actions (login required)
 |
Edit item |